Liraglutide pretreatment attenuates sepsis-induced acute lung injury

被引:15
|
作者
Baer, Brandon [1 ]
Putz, Nathan D. [1 ,2 ]
Riedmann, Kyle [2 ]
Gonski, Samantha [1 ]
Lin, Jason [1 ]
Ware, Lorraine B. [1 ,2 ]
Toki, Shinji [1 ]
Peebles Jr, R. Stokes [1 ,2 ,3 ,4 ]
Cahill, Katherine N. [1 ]
Bastarache, Julie A. [1 ,2 ,3 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37235 USA
[2] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN USA
[3] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA
[4] US Dept Vet Affairs, Nashville, TN USA
关键词
acute lung injury; GLP-1 receptor activation; liraglutide; lung edema; lung inflammation; RESPIRATORY-DISTRESS-SYNDROME; FATTY LIVER-DISEASE; PROTEIN-KINASE-A; NF-KAPPA-B; OXIDATIVE STRESS; INFLAMMATORY CYTOKINES; CALORIE RESTRICTION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; PEPTIDE-1; ANALOG;
D O I
10.1152/ajplung.00041.2023
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
There are no effective targeted therapies to treat acute respiratory distress syndrome (ARDS). Recently, the commonly used diabetes and obesity medications, glucagon-like peptide-1 (GLP-1) receptor agonists, have been found to have anti-inflammatory properties. We, therefore, hypothesized that liraglutide pretreatment would attenuate murine sepsis-induced acute lung injury (ALI). We used a two-hit model of ALI (sepsis+hyperoxia). Sepsis was induced by intraperitoneal injection of cecal slurry (CS; 2.4 mg/g) or 5% dextrose (control) followed by hyperoxia [HO; fraction of inspired oxygen (FIO2) = 0.95] or room air (control; FIO2 = 0.21). Mice were pretreated twice daily with subcutaneous injections of liraglutide (0.1 mg/kg) or saline for 3 days before initiation of CS+HO. At 24-h post CS+HO, physiological dysfunction was measured by weight loss, severity of illness score, and survival. Animals were euthanized, and bronchoalveolar lavage (BAL) fluid, lung, and spleen tissues were collected. Bacterial burden was assessed in the lung and spleen. Lung inflammation was assessed by BAL inflammatory cell numbers, cytokine concentrations, lung tissue myeloperoxidase activity, and cytokine expression. Disruption of the alveolar-capillary barrier was measured by lung wet-to-dry weight ratios, BAL protein, and epithelial injury markers (receptor for advanced glycation end products and sulfated glycosaminoglycans). Histological evidence of lung injury was quantified using a five-point score with four parameters: inflammation, edema, septal thickening, and red blood cells (RBCs) in the alveolar space. Compared with saline treatment, liraglutide improved sepsis-induced physiological dysfunction and reduced lung inflammation, alveolar-capillary barrier disruption, and lung injury. GLP-1 receptor activation may hold promise as a novel treatment strategy for sepsis-induced ARDS. Additional studies are needed to better elucidate its mechanism of action. NEW & NOTEWORTHY In this study, pretreatment with liraglutide, a commonly used diabetes medication and glucagon-like peptide-1 (GLP-1) receptor agonist, attenuated sepsis-induced acute lung injury in a two-hit mouse model (sepsis + hyperoxia). Septic mice who received the drug were less sick, lived longer, and displayed reduced lung inflammation, edema, and injury. These therapeutic effects were not dependent on weight loss. GLP-1 receptor activation may hold promise as a new treatment strategy for sepsis-induced acute respiratory distress syndrome.
引用
收藏
页码:L368 / L384
页数:17
相关论文
共 50 条
  • [41] Pretreatment with Coenzyme Q10 Combined with Aescin Protects against Sepsis-Induced Acute Lung Injury
    Ali, Fares E. M.
    Ahmed, Salwa F.
    Eltrawy, Amira H.
    Yousef, Reda S.
    Ali, Howaida S.
    Mahmoud, Amany R.
    Abd-Elhamid, Tarek H.
    CELLS TISSUES ORGANS, 2021, 210 (03) : 195 - 217
  • [42] Ghrelin attenuates sepsis-induced acute lung injury (ALI) via inhibition of NF-κB.
    Wu, RQ
    Dong, WF
    Zhou, M
    Ravikumar, TS
    Wang, P
    CRITICAL CARE MEDICINE, 2005, 33 (12) : A7 - A7
  • [43] Metabolomics of sepsis-induced acute lung injury: a new approach for biomarkers
    Lacy, Paige
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2011, 300 (01) : L1 - L3
  • [44] Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury
    Park, Inwon
    Kim, Mingyo
    Choe, Kibaek
    Song, Eunjoo
    Seo, Howon
    Hwang, Yoonha
    Ahn, Jinhyo
    Lee, Seung-Hyo
    Lee, Jae Hyuk
    Jo, You Hwan
    Kim, Kyuseok
    Koh, Gou Young
    Kim, Pilhan
    EUROPEAN RESPIRATORY JOURNAL, 2019, 53 (03)
  • [45] Curcumin Protects Against Sepsis-Induced Acute Lung Injury in Rats
    Xiao, Xuefei
    Yang, Mingshi
    Sun, Dao
    Sun, Shenghua
    JOURNAL OF SURGICAL RESEARCH, 2012, 176 (01) : E31 - E39
  • [46] ERRα protects against sepsis-induced acute lung injury in rats
    Xia, Wenfang
    Pan, Zhou
    Zhang, Huanming
    Zhou, Qingshan
    Liu, Yu
    MOLECULAR MEDICINE, 2023, 29 (01)
  • [47] Gallic Acid Protects from Sepsis-Induced Acute Lung Injury
    Kardas, Sueleyman
    Cinaroglu, Osman Sezer
    Bora, Ejder Saylav
    Erbas, Oytun
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (01) : 1 - 10
  • [48] Potential mechanism and drug candidates for sepsis-induced acute lung injury
    Xu, Chenyuan
    Guo, Zhengqiang
    Zhao, Chuncheng
    Zhang, Xufeng
    Wang, Zheng
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (06) : 4689 - 4696
  • [49] Acacetin Attenuates Sepsis-induced Acute Lung Injury via NLRC3-NF-κB Pathway
    Xiao, Yingchou
    Zhang, Bo
    Hou, Shiyuan
    Shen, Xing
    Wu, Xingan
    Liu, Rongrong
    Luo, Ying
    INFLAMMATION, 2025, 48 (01) : 75 - 88
  • [50] IBUPROFEN ATTENUATES PLASMA TUMOR-NECROSIS-FACTOR ACTIVITY DURING SEPSIS-INDUCED ACUTE LUNG INJURY
    LEEPERWOODFORD, SK
    CAREY, PD
    BYRNE, K
    FISHER, BJ
    BLOCHER, C
    SUGERMAN, HJ
    FOWLER, AA
    JOURNAL OF APPLIED PHYSIOLOGY, 1991, 71 (03) : 915 - 923